Objectives
bronchiectasis, airway hyperresponsiveness
ADVERSE EVENTS, AIRWAY HYPERRESPONSIVENESS, BRONCHIECTASIS
The primary objective of this study is to evaluate the presence of airway hyperresponsiveness during the tolerance test in patients treated with TIS as compared with placebo. Secondary objectives were time to first signs of airway hyperresponsiveness for patients treated with TIS as compared with placebo, number of treatment‐related adverse events, and etiology of bronchiectasis patients in whom intolerability of the inhaled medication occurs.